Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2012

View Archived Issues

Chong Kun Dang Pharmaceutical divulges new CETP inhibitors

Researchers at Nutek Pharma prepare new anesthetic agents

Phase I trial of IMO-8400 begins, preclinical results presented

PTC-596 shows efficacy in a number of tumor models in vivo

Data presented on a novel EGFR inhibitor for patients with lung cancer

AstraZeneca will not exercise the option to acquire diabetes assets from Prosidion

Evotec and Haplogen partner to develop drugs for viral infectious diseases

Plasma ADMA as a biomarker to monitor PAH-targeted treatments

Tranzyme Pharma reports topline results from TZP-102 trial

TissueGene completes enrollment in phase II study of TG-C

Inovio Pharmaceuticals expands synthetic vaccine license with University of Pennsylvania

Bavarian Nordic's MVA-BN vaccine platform receives U.S. government contracts

Chinese researchers present new agents for HIV

Nanosphere receives FDA clearance to market test for CYP2C19 mutation

Merck & Co. prepares new NS5B inhibitors

RXi reports pharmacokinetic results from phase I study of candidate for dermal scarring

U.S. Department of Health & Human Services reports novel PLK1 inhibitor compounds

DNDi identifies chemical series targeting two neglected diseases

Epizyme and Eisai patent novel agents for cancer

Fujifilm provides update on development of micro-needle array delivery technology

Forest Laboratories and Adamas to develop fixed-dosed combination for Alzheimer's

Positive in vivo results support the advance of TVB-2640 into clinical studies

Immunovative Therapies expands collaboration with the University of Arizona

Investigators begin study of CNDO-201 in autism spectrum disorders

FDA approves Zilver PTX drug-eluting stent for peripheral arterial disease

New causative gene identified for primary torsion dystonia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...